Microbiology automation company LBT Innovations has sold five APAS Independence laboratory instruments to pharmaceutical manufacturer AstraZeneca AB and will provide maintenance and support services over seven years. The total contract value is worth up to $4.1 million depending on the level of services required, and is in addition to the lease of a sixth instrument…
Laboratory automation manufacturer LBT Innovations has announced that its APAS PharmaQC automated pharmaceutical manufacturing quality control system was now commercially ready after an extensive period of R&D. Primary validation of the device has been completed and the technology formally released to pharmaceutical manufacturer AstraZeneca, a partner in the development. APAS PharmaQC provides automated imaging, analysis…
Microbiology diagnostic equipment manufacturer LBT Innovations has fully written down the value of its major business centred on its APAS technology. The company has recognised a non-cash impairment of $13.4 million which is the full carrying value of the company’s intangible assets related to APAS, as well as a non cash write off of around…
Microbiology diagnostic equipment manufacturer LBT Innovations has partnered with AstraZeneca and Thermo Fisher to speed up the development of LBT’s APAS AI software platform for microbial testing in the pharmaceutical sector. The software, seen on LBT’s APAS Independence laboratory instrument, speeds up the laboratory processing of clinical samples by utilising AI to scan for microbial…
Microbiology diagnostic equipment manufacturer LBT Innovations has been awarded $1.5 million in federal government funding to support further development of the company’s APAS Independence laboratory instrument (pictured). The funding from the Medical Future Fund through MTPConnect’s clinical translation and commercialisation medtech programme will support development of a new, smaller benchtop version of the APAS instrument,…
Microbiology diagnostic device manufacturer LBT Innovations has signed up leading diagnostics group Beckman Coulter as its distributor for the European Union. The company has been commercialising its APAS Independence laboratory instrument (pictured below), an imaging, interpretation, sorting and reporting machine that automatically examines culture plates for the presence of bacterial colonies. Beckman Coulter has signed…
Medical technology and equipment developer LBT Innovations (ASX: LBT) has made its first European sale of its APAS Independence laboratory instrument (pictured). The sale was made to one of the largest clinical laboratories in the EU, Labor Dr Wisplinghoff, which employes more than 40 medical specialists. Laboratory director Professor Hilmar Wilplinghoff joined LBT Innovations CEO…
Medical technology developer LBT Innovations (ASX: LBT) has won European CE mark certification for its APAS Independence laboratory instrument, allowing sale in all European countries. The company has identified 130 priority customers among laboratories in Europe, and will follow its successful strategy of placing its instruments with the laboratories for performance evaluation. APAS is an…
LBT Innovations Ltd’s APAS Independence machine has been tested on laboratory specimens from 4,603 patients at America’s prestigious Johns Hopkins Hospital and passed with a perfect, or perhaps better than perfect, result. The APAS Independence technology uses an algorithm to detect bacterial colonies on laborature culture slides and incorporates computer vision to hasten the time…
Based in Adelaide, South Australia, health technology company LBT Innovations told investors this morning it had completed the sale to Hennepin County Medical Center in Minneapolis
